Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 May 16:12:1509-1511.
doi: 10.2147/JPR.S190171. eCollection 2019.

Tapentadol: a new option for the treatment of cancer and noncancer pains

Anthony H Dickenson  1 , Hans G Kress  2
Affiliations
Editorial

Tapentadol: a new option for the treatment of cancer and noncancer pains

Anthony H Dickenson et al. J Pain Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure AHD has received fees from Grünenthal GmbH, Allergan, Janssen, Johnson & Johnson, Teva, and Regeneron. HGK has received speaker’s and/or consultancy fees from Bionorica SE, Grunenthal GmbH, Mundipharma Int., TEVA Ratiopharm, Mylan, and Pfizer outside the submitted work. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

References

    1. Bannister K, Kucharczyk M, Dickenson AH. Hopes for the future of pain control. Pain Ther. 2017;6(2):117–128. - PMC - PubMed
    1. Zajączkowska R, Przewłocka B, Kocot-Kępska M, Mika J, Leppert W, Wordliczek J. Tapentadol – A representative of a new class of MOR-NRI analgesics. Pharmacol Rep. 2018;70(4):812–820. - PubMed
    1. Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs. 2014;28(4):319–329. - PubMed
    1. Tzschentke TM, Christoph T, Kögel B, et al. (-)-(1R,2R)-3-(3-dimeth-ylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323(1):265–276. - PubMed
    1. Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. Is tapen-tadol different from classical opioids? A review of the evidence. Br J Pain. 2016;10(4):217–221. - PMC - PubMed

Publication types